KTB Klinik für Tumorbiologie GmbH & Co. KG (“KTB Klinik für Tumorbiologie”) and its subsidiary KTB Tumorforschungsgesellschaft mbH filed for insolvency in April 2015. PwC M&A was mandated as exclusive financial advisor by the insolvency administrators of the respective companies, Christopher Seagon and Henrik Schmoll.
We initiated a competitive auction process with regional, national and international strategic and selected financial investors including Chinese bidders, to sell KTB Klinik für Tumorbiologie.
Universitätsklinikum Freiburg acquired KTB Klinik für Tumorbiologie on 20th August 2015 after a highly competitive process based on an offer, which was compelling with regard to its strategic, structural and financial elements. The new investor will support the company in its future development and help realize synergies with existing activities of Universitätsklinikum Freiburg.
KTB Klinik für Tumorbiologie is a comprehensive specialised and leading center for cancer medicine. It comprises the Department of Medical Oncology and the Department of Oncological Rehabilitation and Post Acute Care as well as the Tumor Biology Research Center (KTB Tumorforschungsgesellschaft mbH). With a multidisciplinary team of cancer specialists, KTB Klinik für Tumorbiologie is able to treat a wide range of cancer diagnoses applying both standard methods as wells as innovative therapies (clinical trials). It employs a total of 260 staff.
Universitätsklinikum Freiburg is the teaching hospital of the Albert-Ludwigs-Universität Freiburg and was founded in 1457. It engages in acute care, research and teaching. The Universitätsklinikum has 1,902 beds. More than 10,600 employees - 1,400 doctors and 2,900 nurses – take care of about 66,000 impatient admissions per year.
The global PricewaterhouseCoopers network is a worldwide association of independent auditing and consulting companies which together employ more than 195,000 employees in 157 countries. Our global network comprises nearly 1,550 M&A professionals all over the world, realizing approx. 390 successful transactions per year. We specialize in a wide range of independent M&A services including advice on acquisitions and disposals, mergers, public takeovers, privatizations as well as structured financing.
The PwC M&A team in Germany acted as exclusive financial advisor to the insolvency administrator of KTB Klinik für Tumorbiologie GmbH & Co. KG.
The following PwC M&A team members were involved: Matthias Loos (Partner), Kai Drigalla (Senior Manager), Janika Bierfreund and Maximilian Jähn (both Consultants).
For further information please contact: Alexander von Friesen on +49 69 9585-5487.
Partner, Co-Head Mergers & Acquisitions: Automobilindustrie, Industrielle Produktion
Tel.: +49 69 9585-5667
Dr. Alexander von Friesen
Partner, Co-Head Mergers & Acquisitions: Gesundheitswesen, Handel und Konsumgüter
Tel.: +49 69 9585-5487